Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax

Vaccine

Volumn 25, Issue 10, 2007, Pages 1780-1788

  Semenova, V A ^a   Schmidt, D S ^a   Taylor Jr , T H ^a   Li, H ^a   Steward Clark, E ^a   Soroka, S D ^a   Ballard, M M ^a   Quinn, C P ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Anthrax; Anti PA antibody; AVA; Bacillus anthracis; BioThrax ; IgG subclasses

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4;

ADULT; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; CLINICAL ARTICLE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; VACCINATION;

ADULT; AGED; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ANTITOXINS; BACTERIAL TOXINS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED;

EID: 33846613298     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.11.028     Document Type: Article

References (35)

1. Downloaded from http://www.emergentbiosolutions.com/pdf/emergent_biothrax_us.pdf. [accessed on October 20, 2006].
2. Ivins B.E., and Welkos S.L. Recent advances in the development of an improved, human anthrax vaccine. Eur J Epidemiol 4 1 (1988) 12-19
3. Little S.F., Ivins B.E., Fellows P.F., and Friedlander A.M. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 65 12 (1997) 5171-5175
4. Little S.F., and Ivins B.E. Molecular pathogenesis of Bacillus anthracis infection. Microbes Infect 1 2 (1999) 131-139
5. Little S.F., Ivins B.E., Fellows P.F., Pitt M.L., Norris S.L., and Andrews G.P. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22 3/4 (2004) 422-430
6. Turnbull P.C., Broster M.G., Carman J.A., Manchee R.J., and Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun 52 2 (1986) 356-363
7. Quinn C.P., Semenova V.A., Elie C.M., Romero-Steiner S., Greene C., Li H., et al. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human Immunoglobulin G antibodies to anthrax protective antigen. Emerg Infect Dis 8 10 (2002) 1103-1110
8. Quinn C.P., Dull P.M., Semenova V.A., Li H., Crotty S., Taylor Jr. T.H., et al. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis 190 1 (2004) 1228-1236
9. Baillie L.W.J., Fowler K., and Turnbull P.C.B. Human immune responses to the UK human anthrax vaccine. J Appl Microbiol 87 2 (1999) 306-308
10. McBride B.W., Mogg A., Telfer J.L., Lever M.S., Miller J., Turnbull C.P.B., et al. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 16 8 (1998) 810-817
11. Jefferis R. Structure-function relationships of IgG subclasses. In: Shakib F. (Ed). The human IgG subclasses: molecular analysis of structure, function and regulation (1990), Pergamon Press Inc., Elmsford, NY 93-108
12. Hamilton R.G. The human IgG subclasses. Calbiochem (1998)
13. Brachman P., Gold H., Plotkin S.A., Fekety F.R., Werrin M., and Ingraham N.R. Field evaluation of a human anthrax vaccine. Am J Public Health 52 4 (1962) 632-645
14. Semenova V.A., Steward-Clark E., Stamey K.L., Taylor Jr. T.H., Schmidt D.S., Martin S.M., et al. Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum. Clin Diagn Lab Immunol 11 5 (2004) 919-923
15. Leppla S.H. Purification and characterization of adenylyl cyclase from Bacillus anthracis. In: Johnson A., and Corbin J.D. (Eds). Methods in immunology 19 (1991), Academic Press, San Diego 153-158
16. Park S., and Leppla S.H. Optimized production and purification of Bacillus anthracis lethal factor. Protein Exp Purif 18 3 (2000) 293-302
17. Reimer C.B., Phillips D.J., Aloisio C.H., Moore D., Galland G.G., Wells T.W., et al. Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes. Hybridoma 3 3 (1984) 263-273
18. Jefferis R., Reimer C.B., Skvaril F., deLange G., Ling N.R., Lowe J., et al. Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study. Immunol Lett 10 3/4 (1985) 223-230
19. Downloaded from http://www.cdc.gov/ncidod/dbmd/bimb/elisa.htm. [accessed on September 25, 2004].
20. Plikaytis B.D., Holder P.F., Pais L.B., Maslanka S.E., Gheesling L.L., and Carlone C. Determination of parallelism and nonparallelism in bioassay dilution curves. J Clin Microbiol 2 10 (1994) 2441-2447
21. O'Connell M.A., Belanger B.A., and Haaland P.D. Calibration and assay development using the four-parameter logistic model. Chemometr Intell Lab Syst 20 2 (1993) 97-114
22. Baillie L., Townend T., Walker N., Eriksson U., and Williamson D. Characterization of the human immune response to the UK anthrax vaccine. FEMS Immun Med Microbiol 42 2 (2004) 267-270
23. Bradwell AR. IgG and IgA subclasses in disease. The Binding Site, 1995. p. 29.
24. Scott M.G., Briles D.E., and Nahm M.H. Selective IgG subclass expression: biologic, clinical and functional aspects. In: Shakib F. (Ed). The human IgG subclasses: molecular analysis of structure, function and regulation (1990), Pergamon Press Inc., Elmsford, NY 161-183
25. Hammarstrom L., and Smith C. IgG subclasses changes in bacterial infections. Monogr Allerg 19 (1986) 122-133
26. Linde A., Sundquiist V.A., Mathiesen T., and Wahren B. IgG susclasses to subviral components. Monogr Allerg 23 (1988) 27-32
27. Sanders L.A.M., Rijkers G.T., Tenbergen-Meekers A.M., Voorhorst-Ogink M.M., and Zegers B.J.M. Immunoglobulin isotype-specific antibody responses to pneumococcal polysaccharide vaccine in patients with recurrent bacterial respiratory tract infection. Pediatr Res 37 6 (1995) 812-819
28. Gregorek H., Madaliński K., Woynarowski M., Mikołajewicz J., Syczewska M., and Socha J. The IgG subclass profile of anti-HBs response in vaccinated children and children seroconverted after natural infection. Vaccine 18 13 (2000) 1210-1217
29. Isa M.B., Martinez L., Giordano M., Passeggi C., de Wolf M.C., and Nates S. Comparison of immunoglobulin G subclass profiles induced by measles virus in vaccinated and naturally infected individuals. Clin Diagn Lab Immunol 9 3 (2002) 693-697
30. Zackrisson G., Lagergard T., and Trollfors B. Subclass compositions of immunoglobulin G to pertussis toxin in patients with whooping cough, in healthy individuals, and in recipients of a pertussis toxoid vaccine. Clin Microb 27 7 (1989) 1567-1571
31. Hocart M.J., Mackenzie J.S., and Steward G.A. Serum IgG subclass responses of humans to inactivated and live influenza A vaccines compared to natural infections with influenza A. Med Virol 30 2 (1990) 92-96
32. Welkos S., Little S., Friedlander A., Fritz D., and Fellows P. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147 Pt 6 (2001) 1677-1685
33. Welkos S., Friedlander A., Weeks S., Little S., and Mendelson I. In-vitro characterization of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody. J Med Microbiol 51 10 (2002) 821
34. Devey M.E. Affinity of IgG subclass antibodies. In: Shakib F. (Ed). The human IgG subclasses: molecular analysis of structure, function and regulation (1990), Pergamon Press Inc., Elmsford, NY 185-194
35. Taylor T, Quinn C, Schmidt D, Freeman A, Li H, Semenova V, Hoekstra R, Plikaytis B. Novel mathematical approach to TNA endpoints. Abstracts of the 5th International Meeting on Anthrax, Nice, France, March 31-April 4, 2003.